Economic Evaluation of Lumos Diagnostics’ FebriDx Point-of-Care Test Highlights $2.5 Billion in Potential U.S. Healthcare Cost Savings Annually
6 October 2021
Lumos Diagnostics (ASX: LDX) has today announced that the Journal of Health Economics and Outcomes Research (JHEOR) has published results of a study concluding that using FebriDx® to guide antibiotic treatment for patients presenting with acute respiratory infections (ARIs) could potentially result in up to $2.5 billion of annual cost saving for the U.S. healthcare system.
The journal article is entitled, "Economic Evaluation of FebriDx®: a Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United States" and was authored by Avalon Health Economics.
The study estimates the healthcare costs associated with current antibiotic prescribing, including the cost associated with treating of antibiotic-related adverse events, and compared them with an estimate of the costs when FebriDx is used.
FebriDx can be used to rapidly and accurately distinguish ARI patients with a bacterial infection, who require treatment with an antibiotic, from those with a viral infection, who do not.
Significant findings from the study include:
“Rapid, accurate and actionable information can help increase diagnostic certainty and reduce healthcare costs,” said John Schneider PhD, CEO of Avalon Health Economics.
“FebriDx is a simple fingerstick blood test that differentiates viral from bacterial acute respiratory infection and thereby helps doctors focus antibiotic treatment where it is needed to combat the growing threat of antibiotic resistance.”
Click here to read the ASX announcement
The journal article is entitled, "Economic Evaluation of FebriDx®: a Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United States" and was authored by Avalon Health Economics.
The study estimates the healthcare costs associated with current antibiotic prescribing, including the cost associated with treating of antibiotic-related adverse events, and compared them with an estimate of the costs when FebriDx is used.
FebriDx can be used to rapidly and accurately distinguish ARI patients with a bacterial infection, who require treatment with an antibiotic, from those with a viral infection, who do not.
Significant findings from the study include:
- Over half the prescriptions issued during 150 million outpatient visits for acute respiratory infections (ARIs) each year in the U.S. are considered medically unnecessary
- Antibiotic-related adverse events are responsible for 16% of all outpatient adverse drug consultations
- Outpatient visits accounted for the majority of the US$8.8 billion antibiotic-related expenditure in the U.S. in 2015
“Rapid, accurate and actionable information can help increase diagnostic certainty and reduce healthcare costs,” said John Schneider PhD, CEO of Avalon Health Economics.
“FebriDx is a simple fingerstick blood test that differentiates viral from bacterial acute respiratory infection and thereby helps doctors focus antibiotic treatment where it is needed to combat the growing threat of antibiotic resistance.”
Click here to read the ASX announcement
